“The market ... said a new non-opioid pain medication is positive but it’s too early to claim that suzetrigine poses no ...

Early clinical trial results suggest that a groundbreaking new antibiotic drug could be a “massive game changer” for some patients suffering from chronic lower back pain.

NEW PAIN MEDICATION HAS BEEN APPROVED BY THE ... BY THE FDA AND WILL BE AVAILABLE WI Not a moment too soon: a drug is on the market that is effective in treating pain but is not addictive.Its ...

CHATHAM, NJ / ACCESS Newswire / March 31, 2025 /This post was written and published as a collaboration between the in-house ...

Cheap opioids have long dominated the pain drug market. At a list price of $31 a ... reflecting the unmet need for new treatment options and the promise of Journavx in acute pain, and we continue ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

The FDA approved the drug Zohydro ... when new painkillers entered the market without clear guidance on how they should be prescribed. With the rise of opioid pain management over the past two ...

Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel the growth of the market. However, drug exploitation, patent expiration of prescription pain ...

But without large-scale human trials, the drug would never receive the FDA approval necessary to bring the drug to market ... a brand new housing project complete with running water and sunny ...

The FDA approves a new non-opioid pain pill, Journavx, to treat acute pain in adults. It's a first-generation non-addictive pain medicine.

The long quest for powerful non-opioid drugs that treat pain without risk of addiction is nearing a milestone, in the form of a pill that could soon win approval from the Food and Drug Administration ...